Drug Design

News Drug Design

• European Investment Fund and K.U.Leuven invest 16 million euro in Centre for Drug Design and Discovery

  The Katholieke Universiteit Leuven and the European Investment Fund (EIF) are investing an additional 16 million euro in the Centre for Drug Design and Discovery (CD3), thereby increasing the total capital of CD3 to 24 million euro. CD3 allows fundamental innovative biomedical research carried out more

• Katholieke Universiteit Leuven enters into license agreement with Pfizer for the development of new anti-HIV drugs

  Katholieke Universiteit Leuven (K.U.Leuven, Belgium) announced that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise K.U.Leuven’s compounds with a new mechanism more

• Argenta expands collaboration with Genentech to include BioFocus

  Argenta, a service division of Galapagos NV, announced it has signed a contract extension with Genentech, Inc., a member of the Roche Group. The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapa more

White papers Drug Design

• Alliances in Drug Discovery - The Chemical Element
  

  Alliances have evolved into a critical cornerstone of R&D strategy in the global pharmaceutical industry. No other industry has been leveraging this business model as successfully as the global pharmaceutical industry in its drive for innovation and success. Over three thousand deals amounting to a cumulative payout of US$ 17bn have been signed by pharmaceutical and biotech players in a span of two decades. In the past five years the industry's mania to develop new generation blockbuster drugs has taken on a new sense of urgency as 64% of the alliance value was inked and paid out during the period. more

Publications Drug Design

• Towards an efficient approach to identify molecular scaffolds possessing selective or promiscuous compounds

  Abstract The concept of a recurrent scaffold present in a series of structures is common in medicinal drug discovery. We present a scaffold analysis of compounds screened across 100 sequence‐unrelated proteins to identify scaffolds that drive promiscuity or selectivity. Selectivity and promiscui more

• [Report] Structural Basis for Molecular Recognition at Serotonin Receptors

  Structures of serotonin receptor family members in complex with the fungal alkaloid ergot offer clues for drug designers. [Also see Perspective by Palczewski and Kiser] more

• [Report] Structural Features for Functional Selectivity at Serotonin Receptors

  Structures of serotonin receptor family members in complex with the fungal alkaloid ergot offer clues for drug designers. [Also see Perspective by Palczewski and Kiser] more

Market studies Drug Design

• PharmaGap Inc. (GAP) - Financial and Strategic SWOT Analysis Review

  Pharmagap Inc. (Pharmagap) is biotechnology company, that is engaged in clinical development of innovative therapeutics for several types of cancer. The company develops its lead drug candidate, GAP-107B8 that targets protein Kinase C in the pre-clinical development stage for the treatment of cancer more

• Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs

  GBI Research has released its latest report, “Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs” that provides key data, information and analysis of the major trends and developments in the drug more

Websites Drug Design